BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

Summary

The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20 antibody.

Timeline

Start

2016-10-27

Primary completion

2020-03-19

Completion

2020-03-19

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients” issuerdirect.com ↗

release “Of the 9 patients who completed the induction cycle, 6 patients have shown either complete or partial responses” issuerdirect.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI-1206	Monoclonal antibody	800 mg	Intravenous
Subject	Rituximab	Monoclonal antibody	—	—

Indications